ATAI Life Sciences is reportedly attracting takeover interest from a major U.S. pharmaceutical company. A Betaville alert referenced by traders on July 6, 2026, sparked the speculation. The clinical-stage biopharmaceutical firm develops innovative mental health treatments.
The company recently dosed the final patient in its Phase 2b trial of VLS-01. This clinical trial targets treatment-resistant depression. Topline data for the study are expected in the fourth quarter of 2026.
Shares dropped in the previous session despite the takeover rumors. The stock maintains a significant year-to-date increase following a period of volatility.